Clinical Trial Update: Inetetamab Plus Cyclophosphamide Metronomic Chemotherapy Plus Aromatase Inhibitor in Metastatic HER2+/HR+ Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating inetetamab with metronomic cyclophosphamide and an aromatase inhibitor in metastatic HER2-positive, hormone receptor-po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Inetetamab (inetetamab)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Breast Cancer | Phase 2 | Status: UNKNOWN